Ten-Year Response to Crizotinib in ALK-positive Inflammatory Myofibroblastic Tumors: Case Reports. (2024). Voprosy Onkologii, 70(2), 384-389. https://doi.org/10.37469/0507-3758-2024-70-2-384-389